seekingalpha.com
RaySearch Laboratories AB (publ) (RSLBF) Q4 2025 Earnings Call Transcript
RaySearch Laboratories AB (publ) (RSLBF) Q4 2025 Earnings Call Transcript
RSLBFRSLBFOTC
Loading
Latest News
seekingalpha.com
RaySearch Laboratories AB (publ) (RSLBF) Q3 2025 Earnings Call Transcript
RaySearch Laboratories AB (publ) (OTCPK:RSLBF) Q3 2025 Earnings Call November 7, 2025 4:00 AM EST Company Participants Carolina Stromlid - Head of Investor Relations Johan Löf - Founder, CEO, President & Director Nina Grönberg Conference Call Participants Mattias Vadsten - SEB, Research Division Kristofer Liljeberg-Svensson - DNB Carnegie, Research Division Presentation Carolina Stromlid Head of Investor Relations Good morning and a warm welcome to the presentation of RaySearch Q3 2025 Results. My name is Carolina Stromlid and I'm new Head of Investor Relations at RaySearch.
prnewswire.com
RaySearch Laboratories: Interim report April - June 2025
STOCKHOLM , Aug. 8, 2025 /PRNewswire/ -- SECOND QUARTER (APRIL - JUNE 2025) Order intake amounted to SEK 241.2 M (290.3) Net sales amounted to SEK 304.9 (318.9) Operating profit amounted to SEK 36.4 M (79.3) Profit after tax amounted to SEK 30.8 M (61.4) Earnings per share before/after dilution amounted to SEK 0.90 (1.79) Cash flow from operating activities amounted to SEK 70.6 M (154.6) Order backlog amounted to SEK 1,665.3 M (1,790.5) at the end of the period HALF-YEAR (JANUARY - JUNE 2025) Order intake amounted to SEK 650.8 M (528.8) Net sales amounted to SEK 636.6 M (576.1) Operating profit amounted to SEK 111.2 M (125.1) Profit after tax amounted to SEK 87.6 M (98.1) Earnings per share before/after dilution amounted to SEK 2.55 (2.86) Cash flow from operating activities amounted to SEK 217.4 M (321.9) SIGNIFICANT EVENTS DURING THE SECOND QUARTER Odense University Hospital in Denmark has placed an order and is increasing the level of automation with the RayStation treatment planning system. In May, RayStation v2025 was launched, featuring fast automated treatment planning using machine learning* and the ECHO algorithm, as well as expanded support for treatment planning for patients in the upright position.
prnewswire.com
Interim report January 1 - March 31, 2025: RaySearch Laboratories
STOCKHOLM , May 9, 2025 /PRNewswire/ -- FIRST QUARTER (JANUARY - MARCH 2025) Order intake amounted to SEK 409.6 M (238.5) Net sales amounted to SEK 331.7 M (257.2) Operating profit amounted to SEK 74.8 M (45.8) Profit after tax amounted to SEK 56.8 M (36.7) Earnings per share before/after dilution amounted to SEK 1.66 (1.07) Cash flow from operating activities amounted to SEK 146.8 M (167.3) Order backlog amounted to SEK 1,734.4 M (1,848.0) at the end of the period. SIGNIFICANT EVENTS DURING THE FIRST QUARTER The number of radiation therapy clinics worldwide that have chosen RayStation now exceeds 1,100.
prnewswire.com
RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO
STOCKHOLM , May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories AB (publ) and Vision RT proudly announces the next step in their collaboration: the full integration of MapRT with RayStation®* treatment planning system. This integration enables full access to the MapRT clearance map in RayStation to guide the user during treatment planning in choosing beam trajectories clear from collisions between the treatment unit, patient and couch.
prnewswire.com
Completed placing of shares in RaySearch Laboratories AB (publ)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE OR MAY BE UNLAWFUL. PLEASE REFER TO THE SECTION "IMPORTANT NOTICE" AT THE END OF THIS PRESS RELEASE.
prnewswire.com
Contemplated placement of existing shares in RaySearch Laboratories AB
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE OR MAY BE UNLAWFUL. PLEASE REFER TO THE SECTION "IMPORTANT NOTICE" AT THE END OF THIS PRESS RELEASE.
prnewswire.com
RaySearch Laboratories: Year-end report 2024
STOCKHOLM , Feb. 21, 2025 /PRNewswire/ -- FOURTH QUARTER (OCTOBER - DECEMBER 2024) Order intake SEK 305.0 M (317.7) Net sales SEK 322.7 (299.6) Operating profit SEK 73.6 M (44.4) Profit after tax SEK 60.0 M (31.5) Earnings per share before/after dilution SEK 1.75 (0.92) Cash flow from operating activities SEK 102.9 M (115.8) Order backlog SEK 1,813.2 M (1,864.4) at the end of the period. TWELVE MONTHS (JANUARY – DECEMBER 2024) Order intake SEK 1,087.2 M (1,004.2) Net sales SEK 1,192.0 M (1,022.2) Operating profit SEK 260.5 M (114.9) Profit after tax SEK 203.5 M (81.6) Earnings per share before/after dilution SEK 5.94 (2.38) Cash flow from operating activities SEK 485.2 M (455.9) The Board of Directors proposes a dividend for the full-year 2024 of SEK 3.00 (0.70).
prnewswire.com
RaySearch Laboratories to present ongoing development in liver ablation therapy* at RSNA 2024
STOCKHOLM , Nov. 29, 2024 /PRNewswire/ -- RaySearch will be exhibiting its advanced software solutions at RSNA in Chicago, Illinois, December 1 – 4. RSNA is the largest conference show in the field of radiology which opens new horizons for the company.
prnewswire.com
RaySearch Laboratories: Interim report July - September 2024
STOCKHOLM , Nov. 8, 2024 /PRNewswire/ -- THIRD QUARTER (JULY - SEPTEMBER 2024) Order intake SEK 253.4 M (240.7) Net sales SEK 293.3 (252.9) Operating profit SEK 61.8 M (28,6) Profit after tax SEK 45.4 M (21,6) Earnings per share before/after dilution SEK 1.32 (0.63) Cash flow from operating activities SEK 60.5 M (124.4) Order backlog SEK 1,732.0 M (1,966.3) at the end of the period NINE MONTHS (JANUARY – SEPTEMBER 2024) Order intake SEK 782.1 M (686.5) Net sales SEK 869.4 M (722.5) Operating profit SEK 186.9 M (70.5) Profit after tax SEK 143.5 M (50.0) Earnings per share before/after dilution SEK 4.19 (1.46) Cash flow from operating activities SEK 382.3 M (340.2) SIGNIFICANT EVENTS DURING THE SECOND QUARTER Connect Proton Therapy Center in the USA has placed an order for RayStation Iridium Network first center in the world to use RayCare with TrueBeam to treat a patient SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD GenesisCare in the UK has placed an order for RayStation RaySearch now has more than 100 RayStation customers in China Three centers in the French Unicancer network choose RayStation Nina Grönberg has been appointed as the new CFO and will take office in January 2025 Institut Curie selects RayStation for proton planning The Board has decided to raise the target for the operating margin to at least 25 (20) percent by 2026 WEBCAST CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for July-September 2024 in a webcast to be held in English on Friday, November 8, 2024, at 10:00 a.m. CET. Link to webcast: RaySearch Q3, 2024 The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act.
prnewswire.com
RaySearch Laboratories: Interim report April - June 2024
STOCKHOLM , Aug. 16, 2024 /PRNewswire/ -- SECOND QUARTER (APRIL- JUNE 2024) Order intake SEK 290.3 M (239.2) Net sales SEK 318.9 M (239.5) Operating profit SEK 79.3 M (18.2) Profit after tax SEK 61.4 M (10.9) Earnings per share before/after dilution SEK 1.79 (0.32) Cash flow from operating activities SEK 154.6 M (67.2) Order backlog SEK 1,790.5 M (1,954.9) at the end of the period HALF-YEAR (JANUARY- JUNE 2024) Order intake SEK 528.8 M (445.8) Net sales SEK 576.1 M (469.6) Operating profit SEK 125.1 M (41.9) Profit after tax SEK 98.1 M (28.5) Earnings per share before/after dilution SEK 2.86 (0.83) Cash flow from operating activities SEK 321.9 M (220.9) SIGNIFICANT EVENTS DURING THE SECOND QUARTER Raigmore Hospital in Scotland selects RayCare. RaySearch and C-RAD sign collaboration agreement.
prnewswire.com
RaySearch Laboratories: Interim report January 1 - March 31, 2024
STOCKHOLM , May 17, 2024 /PRNewswire/ -- FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6) Net sales SEK 257.2 M (230.2) Operating profit SEK 45.8 M (23.7) Profit after tax SEK 36.7 M (17.6) Earnings per share before/after dilution SEK 1.07 (0.51) Cash flow SEK 87.9 M (84.5) Order backlog SEK 1,848.0 M (1,903.3) MSEK at the end of the period SIGNIFICANT EVENTS DURING THE FIRTS QUARTER RayStation in more than 1,000 radiotherapy centers worldwide. The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch.
prnewswire.com
RaySearch Laboratories: Year-end report 2023
STOCKHOLM , Feb. 23, 2024 /PRNewswire/ -- FOURTH QUARTER (OCTOBER - DECEMBER 2023) Order intake SEK 317.7 M (514.4) Net sales SEK 299.6 M (264.4) Operating profit SEK 44.4 M (20.7) Profit after tax SEK 31.5 M (14.1) Earnings per share before/after dilution SEK 0.92 (0.41) Cash flow SEK 45.5 M (42.8) Order backlog SEK 1,864.4 M (1,940.1) at the end of the period TWELVE MONTHS (JANUARY - DECEMBER 2023) Order intake SEK 1,004.2 M (1,218.5) Net sales SEK 1,022.2 M (843.6) Operating profit SEK 114.9 M (42.7) Profit after tax SEK 81.6 M (23.8) Earnings per share before/after dilution SEK 2.38 (0.69) Cash flow SEK 190.3 M (46.8) The Board of Directors proposes an ordinary dividend of SEK 0.70 (0) per share which corresponds to 30 percent of the group profit for the period in accordance with the dividend policy. Additionally, the Board of Directors proposes an extra dividend of SEK 1.30 (0) per share.
prnewswire.com
RaySearch Laboratories: Interim report January 1 - September 30, 2023
STOCKHOLM , Nov. 17, 2023 /PRNewswire/ -- THIRD QUARTER (JULY - SEPTEMBER 2023) Order intake SEK 240.7 M (219.1) Net sales SEK 252.9 M (210.9) Operating profit SEK 28.6 M (12.0) Profit after tax SEK 21.6 M (10.1) Earnings per share before/after dilution SEK 0.63 (0.29) Cash flow SEK 63.5 M (-48.0) Order backlog SEK 1,966.3 M (1,715.2) at the end of the period NINE MONTHS (JANUARY - SEPTEMBER 2023) Order intake SEK 686.5 M (704.1) Net sales SEK 722.5 M (579.3) Operating profit SEK 70.5 M (22.0) Profit after tax SEK 50.0 M (9.6) Earnings per share before/after dilution SEK 1.46 (0.28) Cash flow SEK 144.7 M (4.0) SIGNIFICANT EVENTS DURING THE THIRD QUARTER University Medical Center Groningen in the Netherlands purchased Micro-RayStation for pre-clinical research. RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland.
prnewswire.com
Invitation to presentation of RaySearch's interim report for the third quarter of 2023
STOCKHOLM , Oct. 30, 2023 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the third quarter of 2023 on November 17, 2023, at 10.00 am CET. The report will be published on November 17, 2023, at 07.45 am and will be available together with presentation slides on raysearchlabs.com.
prnewswire.com
RaySearch Laboratories : Interim report January 1 - June 30, 2023
STOCKHOLM , Aug. 25, 2023 /PRNewswire/ -- SECOND QUARTER (APRIL-JUNE 2023) Order intake SEK 239.2 M (212.5) Net sales SEK 239.5 M (160.2) Operating profit SEK 18.2 M (-19.5) Profit after tax SEK 10.9 M (-19.7) Earnings per share before/after dilution SEK 0.32 (-0.58) Cash flow SEK -3.3 M (16.7) Order backlog SEK 1,954.9 M (1,540.3) at the end of the period HALF-YEAR (JANUARY-JUNE 2023) Order intake SEK 445.8 M (485.0) Net sales SEK 469.6 M (368.4) Operating profit SEK 41.9 M (10.0) Profit after tax SEK 28.5 M (-0.4) Earnings per share before/after dilution SEK 0.83 (-0.01) Cash flow SEK 81.2 M (52.0) SIGNIFICANT EVENTS DURING THE SECOND QUARTER Yonsei Cancer Center, South Korea, treated its first patient using RayStation and RayCare for carbon ion radiation therapy. New York University Langone Hospital, USA, placed an order for RayStation, which will replace its current treatment planning system.
prnewswire.com
Invitation to presentation of RaySearch's interim report for the second quarter of 2023
STOCKHOLM , Aug. 8, 2023 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2023 on August 25, 2023, at 10.00 am CEST. The report will be published on August 25, 2023, at 07.45 am and will be available together with presentation slides on raysearchlabs.com.
prnewswire.com
UMCG in the Netherlands purchases Micro-RayStation for pre-clinical research, RaySearch Laboratories
STOCKHOLM , July 7, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that University Medical Center Groningen (UMCG) in the Netherlands has placed an order for Micro-RayStation (μ-RayStation), RaySearch's research software platform for radiation treatment planning and plan evaluation in small animal irradiation research. UMCG has been a RaySearch customer since 2013 and use RayStation as their main treatment planning system for external beam proton and photon radiotherapy.